Obesity Press Releases

LUCI by AllyMack Leads the Charge in Natural GLP-1 Alternatives

Biomed Industries, Inc. (Biomed), a leading biopharmaceutical company, announced its latest breakthrough in obesity treatment with the development of NA-931, a triple receptor agonist targeting IGF-1, GLP-1, and GIP hormones.

Other Countries Show What U.S. Should Be Doing About the Obesity Epidemic

Dr. Cynthia Myers-Morrison's Review PARENTAL OBESITY: THE PANDEMIC OF INTERGENERATIONAL PHYSICAL AND MENTAL HEALTH CARNAGE Published in the International Journal of Integrative Pediatrics and Environmental Medicine, April 2023